Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
245 Results for "
DM
" in MedChemExpress (MCE) Product Catalog:
Products (245)
245 Results for "DM" in MCE Product Catalog:
Cat. No.: HY-179602
Research Areas:
PROTAC 11β-HSD1 Degrader 1 is a highly efficient PROTAC targeting 11β-HSD1 (Hydroxysteroid 11-beta dehydrogenase 1). PROTAC 11β-HSD1 Degrader 1 demonstrates ubiquitin-proteasome-dependent degradation of 11β-HSD1. PROTAC 11β-HSD1 Degrader 1 can be used for the study of type 2 diabetes mellitus (T2DM) .
Cat. No.: HY-163996
CAS No.: 2886728-09-0
Research Areas:
DD202-114 is a potent and selective GLP1R agonist. DD202-114 inhibits hERG with an IC50 of 15.9 μM. DD202-114 exhibits strong CYP2C8 inhibition with an IC50 of 0.22 μM. DD202-114 promotes cAMP accumulation. DD202-114 reduces blood glucose levels and food intake. DD202-114 has the potential to be used in the study of type 2 diabetes mellitus (T2DM) and obesity .
Cat. No.: HY-184323
Target:
Research Areas:
PPARγ agonist-24 is a peroxisome proliferator-activated receptor gamma agonist with oral effectiveness, a PPARγ IC50 of 1.752 μM, and a PPARγ Ki of 54.81 nM. PPARγ agonist-24 shows higher selectivity toward PPARγ than PPARα and weak activity toward PPARδ. PPARγ agonist-24 enhances PPARγ protein expression in hepatic cells. PPARγ agonist-24 can be used for the research of type 2 diabetes (t2dm) .
Cat. No.: HY-P86976
Synonyms: HLD1 antibody; Lipophilin antibody; Major myelin proteolipid protein antibody; MMPL antibody; Myelin proteolipid protein antibody; MYPR_HUMAN antibody; PLP 1 antibody; PLP antibody; PLP/DM20 antibody; PLP1 antibody; HLD1 antibody; Lipophilin antibody; Major myelin proteolipid protein antibody; MMPL antibody; Myelin proteolipid protein antibody; MYPR_HUMAN antibody; PLP 1 antibody; PLP antibody; PLP/DM20 antibody; PLP1 antibody; PMD antibody; Proteolipid protein 1 antibody; SPG2 antibody;
Cat. No.: HY-P86977
Synonyms: HLD1 antibody; Lipophilin antibody; Major myelin proteolipid protein antibody; MMPL antibody; Myelin proteolipid protein antibody; MYPR_HUMAN antibody; PLP 1 antibody; PLP antibody; PLP/DM20 antibody; PLP1 antibody; HLD1 antibody; Lipophilin antibody; Major myelin proteolipid protein antibody; MMPL antibody; Myelin proteolipid protein antibody; MYPR_HUMAN antibody; PLP 1 antibody; PLP antibody; PLP/DM20 antibody; PLP1 antibody; PMD antibody; Proteolipid protein 1 antibody; SPG2 antibody;
Cat. No.: HY-P81138
Synonyms: activated leukocyte cell adhesion molecule; ALCAM protein; ALCAM; CD 166; CD166 antigen; FLJ38514; MEMD; MGC71733; FLJ3851; AI853494; BEN; DM-GRASP; MGC27910; MuSC; SC1; CD166_HUMAN.
Cat. No.: HY-N0500
CAS No.: 130567-83-8
Category:
Triterpenes Terpenoids Cucurbitaceae Metabolic Disease Siraitia grosvenorii (Swingle) C. Jeffrey ex Lu et Z. Y. Zhang Plants Disease Research Fields Sweeteners Food Research
Target:
Cat. No.: HY-P81138A
Synonyms: activated leukocyte cell adhesion molecule; ALCAM protein; ALCAM; CD 166; CD166 antigen; FLJ38514; MEMD; MGC71733; FLJ3851; AI853494; BEN; DM-GRASP; MGC27910; MuSC; SC1; CD166_HUMAN.
Cat. No.: HY-178383
Target:
Research Areas:
α-Glucosidase-IN-98 is a potent orally active α-Glucosidase inhibitor with an IC50 of 18.1 μM. α-Glucosidase-IN-98 reversibly binds with α-Glucosidase via hydrogen bonds, electrostatic interactions and hydrophobic effects, which induces significant conformational alterations in the secondary structure of α-Glucosidase. α-Glucosidase-IN-98 decreases postprandial hyperglycemia in Starch (HY-B2225B)/Sucrose (HY-B1779)-challenged mice. α-Glucosidase-IN-98 can be used for type 2 diabetes mellitus (T2DM) research .
Cat. No.: HY-19842
CAS No.: 618380-90-8
Synonyms: CVT 3619
Target:
Research Areas:
GS-9667 (CVT 3619), a novel N 6-5'-substituted adenosine analog, is a selective, partial agonist of the A1 adenosine receptor (A1AdoR). GS-9667 binds to adipocyte membranes with high (KH=14 nM) and low (KL=5.4 μM) affinities. GS-9667 reduces cyclic AMP content and release of nonesterified fatty acids from epididymal adipocytes with IC50 values of 6 nM and 44 nM, respectively. GS-9667 inhibits lipolysis and has the potential for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA) .
Cat. No.: HY-P705536
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: PLP1; Spastic Paraplegia 2, Uncomplicated; Prev. PLP; Pelizaeus-Merzbacher Disease; Prev. SPG2; PLP/DM20; Myelin Proteolipid Protein; HLD1; Lipophilin; MMPL; GPM6C; PMD; Proteolipid Protein 1; Major Myelin Proteolipid Protein
Species:
Human
Source:
E. coli Cell-free
Cat. No.: HY-175590
Target:
Research Areas:
DPP-4-IN-17 is an orally active and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with an IC50 value of 0.12 nM. DPP-4-IN-17 increases the enzyme's Km value (75.73 μM vs. 27.18 μM of substrate alone) and reduces catalytic efficiency. DPP-4-IN-17 reduces blood glucose levels and reverses weight loss in Streptozotocin (STZ) (HY-13753)/Nicotinamide (NA) (HY-B0150)-induced diabetic rats. DPP-4-IN-17 can be used for the study of type 2 diabetes mellitus (T2DM) .
Cat. No.: HY-10450AR
CAS No.: 960404-48-2
Synonyms: BMS-512148 (2S)-1,2-propanediol, hydrate (Standard)
Target:
Research Areas:
Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard) is the analytical standard of Dapagliflozin ((2S)-1,2-propanediol, hydrate). This product is intended for research and analytical applications. Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury .
Cat. No.: HY-123765
CAS No.: 701232-94-2
Target:
Research Areas:
JTT-553 is a DGAT1 inhibitor (IC50: 2.38 nM). JTT-553 reduces plasma concentrations of glucose, insulin, non-esterified fatty acids (NEFA), total cholesterol (TC), and hepatic triglycerides (TG). JTT-553 improves insulin-dependent glucose uptake and glucose intolerance in adipose tissue of DIO mice. JTT-553 reduces TNF-α mRNA levels and increases GLUT4 mRNA levels in adipose tissue of KK-Ay mice. JTT-553 improves adipose tissue insulin resistance and systemic glucose metabolism by reducing body weight. JTT-553 can be used in the study of obesity and type 2 diabetes mellitus (T2DM) .
Cat. No.: HY-155156
Purity: 99.46%
Target:
Research Areas:
Cardiovascular Disease Metabolic Disease Inflammation/Immunology
PF-07238025 is a BCKDC kinase (BDK) inhibitor (EC50=19 nM). PF-07238025 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07238025 improved cardiometabolic endpoints and improves glucose tolerance in mice .
Cat. No.: HY-155157
Purity: 98.66%
Target:
Research Areas:
PF-07247685 is a BCKDC kinase (BDK) inhibitor (EC50=2.2 nM). PF-07247685 stabilizes the interaction between BDK and BCKDH core subunit E2 and prevents phosphorylation of E1. While BDK mediates branched-chain ketoacid dehydrogenase (BCKDH) phosphorylation, and inhibition of BCKDH is involved in controlling the rate-limiting step of branched-chain amino acid (BCAA) degradation. Impaired BCAA catabolism has been associated with several diseases, particularly cardiometabolic diseases, including heart failure (HF), type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), and obesity. PF-07247685 improved cardiometabolic endpoints and improves glucose tolerance in mice .
Cat. No.: HY-149255
Target:
Research Areas:
PTP1B/AKR1B1-IN-2 (Compound 7f) is a dual PTP1B/AKR1B1 inhibitor (IC50s: 3.2 and 2.1 μM, Kis: 4.0 and 0.9μM). PTP1B/AKR1B1-IN-2 is an insulin-mimetic agent. PTP1B/AKR1B1-IN-2 improves glucose uptake in murine C2C12 myoblasts. PTP1B/AKR1B1-IN-2 can be used for research of Type 2 diabetes mellitus (T2DM) .
Cat. No.: HY-178958
CAS No.: 3122526-69-3
Research Areas:
PPAR agonist 7 is an orally active pan-PPAR agonist, demonstrating potent activation of all three subtypes, PPARα (EC50 = 1.51 μM), PPARδ (EC50 = 1.11 μM), and PPARγ (EC50 = 3.14 μM). PPAR agonist 7 significantly enhances glucose uptake in adipocytes while exhibiting minimal adipogenic activity. PPAR agonist 7 can suppress PPARγ Ser273 phosphorylation in white adipose tissue and upregulate insulin-sensitizing genes. PPAR agonist 7 does not cause weight gain or fluid retention in high-fat diet (HFD)/
Streptozotocin (HY-13753) (STZ)-induced type 2 diabetes mellitus (T2DM) models. PPAR agonist 7 has selective modulation of PPAR signaling pathways without activation of adipogenic gene programs. PPAR agonist 7 can be used for the study of diabetes .
Cat. No.: HY-P72165
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Lanosterol 14-alpha demethylase CYP51; EC:1.14.14.154; Cytochrome P450 51; Cytochrome P450-14DM; Cytochrome P450-LIA1; CYPLI; Ergosterol biosynthetic protein 11; Lanosterol C14-C32 lyase; Sterol 14-alpha demethylase; ERG11; CYP51; YHR007C
Species:
Others
Source:
E. coli
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
